Timothy Wilkin Timothy Wilkin, Weill Cornell Medical College, New York A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed mult
Timothy Wilkin
Timothy Wilkin, Weill Cornell Medical College, New YorkA protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed multiple regimens. Six month data have now yielded dose and toxicity findings and some preliminary recommendations for therapeutic use.
Related Episodes
Audio Journal of Oncology Volume 16 Number 9
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod
New Targets Bring Promise For Lung Cancer Therapy
Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w